Mark Christopher Markowski, MD, PhD, Johns Hopkins Medicine, Baltimore, MD, discusses treatment sequencing for metastatic castration-resistant prostate cancer (mCRPC), which still remains to be determined, particularly with the introduction of newer experimental compounds such as lutetium PSMA. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

свернуть